Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Linagliptin Pharmacokinetics
NCT02183584Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the steady state concentration-time curve of linagliptin in plasma up to 19 days and Maximum measured steady state concentration of linagliptin in plasma up to 19 days. Started Sep 2009; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183584.